.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AB11_Valaciclovir.Valaciclovir .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AB11_Valaciclovir.Valaciclovir| name: | Valaciclovir |
| ATC code: | J05AB11 | route: | oral |
| n-compartments | 1 |
Valaciclovir is an antiviral prodrug that is rapidly converted in vivo to acyclovir, an agent used primarily for the treatment of herpes simplex virus (HSV) infections and varicella-zoster virus (VZV) infections. It is approved and commonly used today for herpes simplex (genital herpes, cold sores), herpes zoster (shingles), and, sometimes, for cytomegalovirus prophylaxis in transplant patients.
Pharmacokinetic parameters in healthy adult volunteers after a single oral dose of valaciclovir 1000 mg, values reported for acyclovir (active metabolite).
Zeng, L, et al., & McLachlan, AJ (2009). Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. Antimicrobial agents and chemotherapy 53(7) 2918–2927. DOI:10.1128/AAC.01138-08 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19414579
Patel, R (1997). Valaciclovir: development, clinical utility and potential. Expert opinion on investigational drugs 6(2) 173–189. DOI:10.1517/13543784.6.2.173 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15989601
Faure-Bardon, V, et al., & Ville, Y (2025). Quantification of maternal and fetal valaciclovir exposure in a pharmacokinetic study of cytomegalovirus-infected pregnant women treated to prevent vertical transmission. The Journal of antimicrobial chemotherapy 80(3) 760–766. DOI:10.1093/jac/dkae470 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39810739